BACKGROUND: Meropenem plus levofloxacin treatment was shown to be a promising combination in our in vitro hollow fiber infection model. We strove to validate this finding in a murine Pseudomonas pneumonia model. METHODS: A dose-ranging study with meropenem and levofloxacin alone and in combination against Pseudomonas aeruginosa was performed in a granulocytopenic murine pneumonia model. Meropenem and levofloxacin were administered to partially humanize their pharmacokinetic profiles in mouse serum. Total and resistant bacterial populations were estimated after 24 hours of therapy. Pharmacokinetic profiling of both drugs was performed in plasma and epithelial lining fluid, using a population model. RESULTS: Meropenem and levofloxacin penetrations into epithelial lining fluid were 39.3% and 64.3%, respectively. Both monotherapies demonstrated good exposure responses. An innovative combination-therapy analytic approach demonstrated that the combination was statistically significantly synergistic (α = 2.475), as was shown in the hollow fiber infection model. Bacterial resistant to levofloxacin and meropenem was seen in the control arm. Levofloxacin monotherapy selected for resistance to itself. No resistant subpopulations were observed in any combination therapy arm. CONCLUSIONS: The combination of meropenem plus levofloxacin was synergistic, producing good bacterial kill and resistance suppression. Given the track record of safety of each agent, this combination may be worthy of clinical trial.
BACKGROUND:Meropenem plus levofloxacin treatment was shown to be a promising combination in our in vitro hollow fiber infection model. We strove to validate this finding in a murinePseudomonaspneumonia model. METHODS: A dose-ranging study with meropenem and levofloxacin alone and in combination against Pseudomonas aeruginosa was performed in a granulocytopenic murine pneumonia model. Meropenem and levofloxacin were administered to partially humanize their pharmacokinetic profiles in mouse serum. Total and resistant bacterial populations were estimated after 24 hours of therapy. Pharmacokinetic profiling of both drugs was performed in plasma and epithelial lining fluid, using a population model. RESULTS:Meropenem and levofloxacin penetrations into epithelial lining fluid were 39.3% and 64.3%, respectively. Both monotherapies demonstrated good exposure responses. An innovative combination-therapy analytic approach demonstrated that the combination was statistically significantly synergistic (α = 2.475), as was shown in the hollow fiber infection model. Bacterial resistant to levofloxacin and meropenem was seen in the control arm. Levofloxacin monotherapy selected for resistance to itself. No resistant subpopulations were observed in any combination therapy arm. CONCLUSIONS: The combination of meropenem plus levofloxacin was synergistic, producing good bacterial kill and resistance suppression. Given the track record of safety of each agent, this combination may be worthy of clinical trial.
Authors: Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano Journal: Antimicrob Agents Chemother Date: 2010-04-05 Impact factor: 5.191
Authors: Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe Journal: Ther Drug Monit Date: 2012-08 Impact factor: 3.681
Authors: Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: G L Drusano; T P Lodise; D Melnick; W Liu; A Oliver; A Mena; B VanScoy; A Louie Journal: Antimicrob Agents Chemother Date: 2011-05-16 Impact factor: 5.191
Authors: George L Drusano; Michael Neely; Michael Van Guilder; Alan Schumitzky; David Brown; Steven Fikes; Charles Peloquin; Arnold Louie Journal: PLoS One Date: 2014-07-08 Impact factor: 3.240
Authors: Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447
Authors: Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Jocelyn Y Ang; Nahed Abdel-Haq; Frank Zhu; Abrar K Thabit; David P Nicolau; Michael J Satlin; David van Duin Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Rajbharan Yadav; Jürgen B Bulitta; Jiping Wang; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: María Montero; Sandra Domene Ochoa; Carla López-Causapé; Brian VanScoy; Sonia Luque; Luisa Sorlí; Núria Campillo; Ariadna Angulo-Brunet; Eduardo Padilla; Núria Prim; Virginia Pomar; Alba Rivera; Santiago Grau; Paul G Ambrose; Antonio Oliver; Juan P Horcajada Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191
Authors: G L Drusano; M N Neely; W M Yamada; Brandon Duncanson; David Brown; Michael Maynard; Michael Vicchiarelli; Arnold Louie Journal: Antimicrob Agents Chemother Date: 2018-11-26 Impact factor: 5.191